ArticleThe Annals of thoracic surgery2023
Ten-Year Follow-up Results of Pure Ground-Glass Opacity-Featured Lung Adenocarcinomas After Surgery.
Article in The Annals of thoracic surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 34 citations in OpenAlex.
- Decoding Malignant Lung Ground Glass Opacities: A Radiologic-Pathologic Study From Pure to Semi-Solid Lesions.Thoracic cancer · 2026Article
- Over- and underscreening for lung cancer.Translational lung cancer research · 2026Review
- LDCT screening for lung cancer in East Asian never-smokers: balancing benefits and overdiagnosis-related harms.The Lancet regional health. Western Pacific · 2026Review
- Pulmonary ground glass opacity tumor: a curable subtype of lung cancer when treated within the "surgical curative time window".Translational lung cancer research · 2026Review
- Sublobar resection is the preferred surgical strategy for clinical stage IA lung cancers presenting as subsolid nodule.JTCVS open · 2026Article
- Proposal on incorporating consolidation-to-tumor ratio into the clinical T1 classification in patients with invasive lung adenocarcinoma.Translational lung cancer research · 2026Article
- [Expert Consensus on Shared Decision-making in the Diagnosis and Treatment of Ground-glass Opacity-featured Lung Adenocarcinoma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Article
- A proposal for selecting appropriate intersegmental plane identification methods based on tumor characteristics in thoracoscopic segmentectomy.Journal of visualized surgery · 2026Article
- Contrast-enhanced computed tomography-based intratumoral and peritumoral radiomics for identifying malignancy in pulmonary ground-glass nodules.Journal of thoracic disease · 2025Article
- The Necessity of Lymphadenectomy for Non-Small Cell Lung Cancer Smaller Than 6 mm in Solid Size.Annals of surgical oncology · 2025Article
- Lung cancer screening in people who have never smoked: lessons from East Asia.BMJ (Clinical research ed.) · 2025Article
- Gene mutation, clinical characteristics and pathology in resectable lung adenocarcinoma.World journal of surgical oncology · 2025Article
- Protocol of a single-arm, multicenter, phase III trial for selective lymph node dissection in cT1N0M0 invasive non-small cell lung cancer with consolidation-tumor ratio >0.5 located in the apical segment: Eastern Cooperative Thoracic Oncology Projects ECTOP-1018 (SELLAS study).Journal of thoracic disease · 2024Article
- Data-driven risk stratification and precision management of pulmonary nodules detected on chest computed tomography.Nature medicine · 2024Article
- Premalignant Progression in the Lung: Knowledge Gaps and Novel Opportunities for Interception of Non-Small Cell Lung Cancer. An Official American Thoracic Society Research Statement.American journal of respiratory and critical care medicine · 2024Review
- The Overlooked Cornerstone in Precise Medicine: Personalized Postoperative Surveillance Plan for NSCLC.JTO clinical and research reports · 2024Review
- A clinical nomogram for predicting occult lymph node metastasis in patients with non-small-cell lung cancer ≤2 cm.Interdisciplinary cardiovascular and thoracic surgery · 2024Article
- Segmentectomy versus lobectomy for ground-glass opacity dominant cT1N0 invasive lung adenocarcinoma.Translational lung cancer research · 2024Article
- Pure ground-glass opacities (GGO) lung adenocarcinoma: surgical resection is curative.Journal of thoracic disease · 2024Article
- Primary lung cancer in children and adolescents.Journal of cancer research and clinical oncology · 2024Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreviously, we have demonstrated that the 5-year recurrence-free survival after surgery of pure ground-glass opacity (GGO)-featured lung adenocarcinoma is 100%. This study aimed to reveal the long-term outcomes of these patients 10 years after surgery.
methodsLung adenocarcinoma patients who underwent surgery between December 2007 and December 2013 were reviewed. Patients with pure GGO-featured lung adenocarcinoma were enrolled. Postoperative survival and the risk of developing second primary lung cancer were analyzed.
resultsOverall, 308 cases of pure GGO-featured lung adenocarcinomas were included. Of these patients, 226 (73.4%) were female, 268 (87.0%) were nonsmokers, and 187 (60.7%) underwent sublobar resection. The median follow-up period after surgery was 112 months. The 10-year recurrence-free survival rate of these patients was 100%, and 10-year overall survival rate was 96.9%. Both 5-year and 10-year lung cancer-specific survival were 100%. There was no difference in 10-year recurrence-free survival rates between patients who underwent lobectomy or sublobar resection (P = .697). EGFR mutations were detected in 55.6% (84 of 151) of patients who underwent mutational analysis. The risk of developing secondary primary lung cancer for pure GGO-featured lung adenocarcinoma patients at 10 years after resection was 2.4%, and was not correlated with EGFR mutation status (P = .452).
conclusionsNo recurrence was observed in patients with pure GGO-featured lung adenocarcinomas 10 years after surgery, even when pathologically evaluated as invasive adenocarcinoma. Pure GGO can be cured by surgery. Surgery is recommended for the appropriate time window with the view to cure. Our study emphasizes that radiologic pure GGO-featured lung adenocarcinomas should be distinguished from other lung adenocarcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.